[go: up one dir, main page]

WO2002008282A3 - Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers - Google Patents

Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers Download PDF

Info

Publication number
WO2002008282A3
WO2002008282A3 PCT/US2001/023574 US0123574W WO0208282A3 WO 2002008282 A3 WO2002008282 A3 WO 2002008282A3 US 0123574 W US0123574 W US 0123574W WO 0208282 A3 WO0208282 A3 WO 0208282A3
Authority
WO
WIPO (PCT)
Prior art keywords
ras
bstp
rerg
provides
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/023574
Other languages
English (en)
Other versions
WO2002008282A2 (fr
Inventor
David Botstein
Patrick O Brown
Channing Der
Chuck Perou
Douglas Ross
Douglas Seitz
Fuyu Tamanoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Applied Genomics Inc
University of California Berkeley
University of California San Diego UCSD
Leland Stanford Junior University
Original Assignee
University of North Carolina at Chapel Hill
Applied Genomics Inc
University of California Berkeley
University of California San Diego UCSD
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Applied Genomics Inc, University of California Berkeley, University of California San Diego UCSD, Leland Stanford Junior University filed Critical University of North Carolina at Chapel Hill
Priority to AU2001277202A priority Critical patent/AU2001277202A1/en
Publication of WO2002008282A2 publication Critical patent/WO2002008282A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002008282A3 publication Critical patent/WO2002008282A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une protéine (BSTP-Ras/Rerg) et des polynucléotides qui identifient et codent BSTP-Ras; ainsi que des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes; des procédés de traitement ou de prévention de troubles liés à la prolifération cellulaire, particulièrement le cancer du sein, au moyen de l'administration d'une composition pharmaceutique comprenant un polypeptide, un polynucléotide ou un anticorps selon l'invention; des procédés de classification des maladies, particulièrement du cancer du sein, au moyen de la détection de l'expression de BSTP-Ras ou d'un polynucléotide codant BSTP-Ras, et de l'utilisation d'informations de diagnostic, de pronostic et/ou de prédiction pour un patient sur la base de la détection et/ou de la mesure de BSTP-Ras ou d'un gène qui code BSTP-Ras ou d'une mutation dans le gène BST-RAS/Rerg.
PCT/US2001/023574 2000-07-26 2001-07-26 Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers Ceased WO2002008282A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277202A AU2001277202A1 (en) 2000-07-26 2001-07-26 Bstp-ras/rerg protein and related reagents and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22096700P 2000-07-26 2000-07-26
US60/220,967 2000-07-26
US23781900P 2000-10-03 2000-10-03
US60/237,819 2000-10-03

Publications (2)

Publication Number Publication Date
WO2002008282A2 WO2002008282A2 (fr) 2002-01-31
WO2002008282A3 true WO2002008282A3 (fr) 2003-09-25

Family

ID=26915368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023574 Ceased WO2002008282A2 (fr) 2000-07-26 2001-07-26 Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers

Country Status (2)

Country Link
AU (1) AU2001277202A1 (fr)
WO (1) WO2002008282A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078662A1 (fr) 2002-03-13 2003-09-25 Genomic Health Profilage d'expression genique dans des tissus tumoraux ponctionnes
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ATE412779T1 (de) 2003-02-20 2008-11-15 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
WO2005039382A2 (fr) 2003-06-24 2005-05-06 Genomic Health Prediction de probabilite de la recurrence d'un cancer
ES2651849T3 (es) 2003-07-10 2018-01-30 Genomic Health, Inc. Algoritmo del perfil de expresión y test para el pronóstico del cáncer
ES2360113T3 (es) 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006052862A1 (fr) 2004-11-05 2006-05-18 Genomic Health, Inc. Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique
EP1815014B1 (fr) 2004-11-05 2012-03-21 Genomic Health, Inc. Indicateurs moléculaires de pronostic du cancer du sein et prédiction de réponse du traitement

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049194A2 (fr) * 1997-04-30 1998-11-05 Incyte Pharmaceuticals, Inc. Nouvelle proteine de type ras
WO1999058677A1 (fr) * 1998-05-13 1999-11-18 Axys Pharmaceuticals, Inc. Genes raq et leurs utilisations
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001054733A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049194A2 (fr) * 1997-04-30 1998-11-05 Incyte Pharmaceuticals, Inc. Nouvelle proteine de type ras
WO1999058677A1 (fr) * 1998-05-13 1999-11-18 Axys Pharmaceuticals, Inc. Genes raq et leurs utilisations
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001054733A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FINLIN B. ET AL.: "RERG is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., vol. 276, no. 45, 31 August 2001 (2001-08-31), US, pages 42259 - 42267, XP002220234 *
GOLUB T R ET AL: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531 - 537, XP002207658, ISSN: 0036-8075 *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
MENDOZA L G ET AL: "HIGH-THROUGHPUT MICROARRAY-BASED ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 27, no. 4, October 1999 (1999-10-01), pages 778,780,782 - 786,788, XP000992893, ISSN: 0736-6205 *
MOSCOW J A ET AL: "Utilization of multiple polyadenylation signals in the human RHOA protooncogene.", GENE. NETHERLANDS 8 JUL 1994, vol. 144, no. 2, 8 July 1994 (1994-07-08), pages 229 - 236, XP002220233, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2002008282A2 (fr) 2002-01-31
AU2001277202A1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
WO2002008261A3 (fr) Proteine bstp-trans et reactifs apparentes, et methodes d'utilisation s'y rapportant
WO2002008260A3 (fr) Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
Jantos-Siwy et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
WO2001055319A3 (fr) Acides nucleiques, proteines et anticorps
WO2001012662A3 (fr) Proteines associees a la membrane
WO1999024463A3 (fr) Proteines contenant une sequence signal
WO2002008282A3 (fr) Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers
WO2002032953A3 (fr) Proteine plasmatique a2 associee a la grossesse (papp-a2)
WO2000015793A3 (fr) Proteines gpcr humaines
WO2000021988A3 (fr) Proteine humaine de la famille des ankyrines
JP2009509169A (ja) 前立腺癌のためのバイオマーカー
WO2000018922A8 (fr) Proteines humaines associees a des glucides
WO1999058692A3 (fr) Proteines associees a l'apoptose humaine
WO2000009709A3 (fr) Proteases et proteines associees
Syrjänen et al. Expression of cancer‐related carbonic anhydrases IX and XII in normal skin and skin neoplasms
Hong et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer
Böhm et al. Hyaluronan expression in differentiated thyroid carcinoma
WO2000052151A3 (fr) Proteines de secretion humaines
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
WO2000056891A3 (fr) Proteines transmembranaires humaines
WO2001007471A3 (fr) Proteines du cycle et de proliferation cellulaires
WO1999061614A3 (fr) Proteines socs humaines
WO2002008281A3 (fr) Proteine bstp-cad et reactifs associes et methodes d'utilisation
WO2001042285A3 (fr) Matrice extracellulaire et molecules d'adherence cellulaire
WO2000070047A3 (fr) Molecules completes exprimees dans des tissus humains

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref document number: 2003132167

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP